abstract |
The compounds provided in the present application are novel substituted pyrazinones, pyridines and pyrimidines of formulas (I) and (II). Because the compounds serve as CRF receptor ligands, they are particularly useful for treating a variety of neurological disorders such as affective disorders, anxiety and depression. |